Dr. Manoj Khatri
Diabetes mellitus is a chronic disease that affects 415 million people worldwide. Despite treatment advances, diabetic eye disease remains a leading cause of vision loss worldwide. Diabetic macular edema (DME) is a
common cause of vision loss in diabetic patients. The pathophysiology is complex and involves multiple pathways that ultimately lead to central retinal thickening and, if untreated, visual loss. First-line treatment of
DME has evolved from focal/grid laser established by the Early Treatment of Diabetic Retinopathy Study (ETDRS) to intravitreous pharmacologic therapy. Landmark prospective clinical trials examining the effect of
intravitreous injections of vascular endothelial growth factor (VEGF) inhibitors in the treatment of DME have demonstrated improved visual outcomes over focal grid laser. This course focuses on the scientific evidence treatment of DME, disease pathophysiology, clinical course, current treatment standards, and emerging novel
therapeutic approaches.
| 1 | Newer Concepts in Understanding the Pathophysiology of DME | Dr. Swapnesh D Sawant | watch video |
| 2 | Newer Diagnostic Investigations in the Management of DME | Dr. Nivean M | watch video |
| 3 | First Line Therapy in the Management of DME | Dr. Mahesh Shanmugam P | watch video |
| 4 | Combination Therapy in the Management of DME | Dr. Manoj Khatri | watch video |
| 5 | Cataract Surgery Along with the Management of DME | Dr. Mohan Rajan | |
| 6 | Emerging Trends in the Management of DME | Dr. Rupesh Vijay Agrawal |
Leave a Comment